Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
95,963,102
-
Total 13F shares
-
94,131,376
-
Share change
-
+5,240,549
-
Total reported value
-
$3,423,160,510
-
Put/Call ratio
-
63%
-
Price per share
-
$36.36
-
Number of holders
-
307
-
Value change
-
+$191,188,594
-
Number of buys
-
167
-
Number of sells
-
150
Institutional Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q2 2025
As of 30 Jun 2025,
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) was held by
307 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
94,131,376 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock, Inc., SANDS CAPITAL MANAGEMENT, LLC, JPMORGAN CHASE & CO, PRICE T ROWE ASSOCIATES INC /MD/, BAKER BROS. ADVISORS LP, FMR LLC, STATE STREET CORP, SUVRETTA CAPITAL MANAGEMENT, LLC, and Clearbridge Investments, LLC.
This page lists
307
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.